Dr. Fu Dian is a clinical oncologist and researcher specializing in genitourinary malignancies at Jinling Hospital, a major cancer center. With a focus on translational research, Dr. Fu’s work investigates the molecular evolution of urothelial carcinoma and the mechanisms underlying response and resistance to novel therapies, including antibody-drug conjugates (ADCs) and targeted agents. This research aims to identify predictive biomarkers and optimize treatment sequencing, as explored in recent literature on the topic. Dr. Fu has contributed to multiple clinical trials and publications in the field of precision oncology for bladder cancer.